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Abstract:  A new approach to modeling protein release kinetics from lipid implants is 
presented. The recently offered model for prediction of protein transfer out of the lipid 
implant simultaneously with two water soluble excipients release is improved. Appropriate 
expressions for concentrations dependent diffusion coefficients are introduced taking into 
account the initial and current implant porosity. A numerical scheme for solving the arisen 
highly nonlinear model problem is also developed on the basis of Finite Element (FE) 
domain approximation and time difference scheme. The new approach and created software 
are validated using available experimental data for protein release, under different initial 
content of the drug release modifier. A good correspondence is obtained and a numerical 
simulation of the effect of the initial implant porosity on drug release profiles is performed. 
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Introduction 
Sustained release systems for pharmaceutical proteins can be regarded as innovative 
pharmaco-therapies, since they offer the possibility to deliver this type of bioactive agents to 
their target sites reducing the administration frequency and enhancing their in vivo stability. 
Non-degradable lipid implants particularly, are reliable alternative of parenteral drug delivery 
systems for protein controlled release. These systems are based on the embedding of protein 
ingredients into a lipid matrix [4-8]. 
 
Recently a mathematical model for description of the simultaneous diffusion of multiple 
compounds (drug-interferon α-2a (INF-α) and water soluble excipients: release modifier – 
polyethylene glycol (PEG); drug stabilizer – hydroxypropyl-β-cyclodextrin (HP-β-CD)) in 
tristearin based implants was presented introducing the effect of matrix porosity [8]. 
According to the authors, “the increase in porosity at a particular position at a particular time 
point is calculated based on the knowledge of INF-α, PEG and HP-β-CD lost at this position 
at this time point”, but there is a lack of mathematical description of the porosity 
concentrations dependence in the paper. The proposed linear dependence between the 
diffusivity of each compound and the current porosity (introducing a critical diffusion 
parameter as a linear coefficient) supposes in advance that the values of the diffusivities 
should be different (much smaller, because the porosity varies from 2% up to 25%, for 
example [5]) from the corresponding diffusion parameters. The estimation of the drug (INF-α) 
diffusion parameter in [8] is approximately equal to the value of the drug diffusivity used for 
explanation of one and the same experimental data with the proposed model and the classical 
diffusion theory, respectively [4]. 
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The aim of the present study is to improve the above model offering a new approach to a 
more accurate and reliable quantitative prediction of protein drug release from lipid implants. 
Explicit mathematical expressions for concentrations dependent diffusion coefficients of 
different compounds are presented within each considered element of the domain, taking into 
account the current porosity increasing in time. A FE approach to solving the arisen highly 
non-linear model problem is also introduced, and noncommercial software is created.   
The developed model is validated using experimental data for INF-α/HP-β-CD and PEG 
release, under different initial PEG loading. The INF-α critical diffusion parameter is 
evaluated for three levels of PEG content fitting the new approach with experimental data. 
Numerical simulation of the effect of initial implant porosity on the protein drug release 
kinetics is performed. 
  
Statement of the model problem 
The release of IFN-α/HP-β-CD from a cylindrical lipid implant of radius R and height 2H, 
containing PEG (10%÷40%), is considered. It is assumed that: (1) the controlling mechanism 
of protein release kinetics is the simultaneous diffusion of IFN-α, HP-β-CD and PEG upon 
contact with biological fluid or water; (2) the initially slight porosity of the lipid matrix 
steadily increases due to IFN-α/HP-β-CD and PEG release from the implant; (3) the diffusion 
coefficients of the dissolved ingredients within the implant are directly related  to the matrix 
porosity which is dependent on their concentrations; (4) water penetration into the implant 
(much faster than the subsequent protein diffusion), as well as matrix swelling and 
dissolution, are negligible; (5) full liberation of each compound is realized; (6) perfect sink 
conditions are maintained [8].  
 
The model equations describing the simultaneous IFN-α, HP-β-CD and PEG diffusion in a 
cylindrical implant corresponding to the domain 
2 Ω ⊂ R (a quarter of the axial cross-section 
due to the symmetry) are as follows:  
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The following relations concerning the effect of increasing porosity can be presented 
according to the model assumptions (2) and (3): 
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where  geom V  and  true V  are an effective volume connected with a representative sub domain of 
Ω which is assumed not to be changed in time and the corresponding volume not containing 
pore space (decreasing in time); ε ,  0123 ,,, ρ ρρ ε  are the considered sub domain porosity, the 
initial implant porosity and the density of IFN-α, HP-β-CD and PEG respectively;  k M ∆  and 
in k
k
k c
t C
t c
) (
) ( =  are the decrease of the mass of k
th diffusing compound in the period (0, t) 
within the considered domain   and the corresponding average current dimensionless 
concentration.  
 
For our future considerations the current porosity is referred to each discrete element of Ω as a 
function of the average element concentrations as follows: 
123
123 0 1 2 3
123
( , , ) (1 ) (1 ) (1 )
in in in ccc
ccc c c c εε
ρρρ
=+ −+ − + −, (6) 
 
The above equations are posed under the following initial and boundary conditions: 
1(,, 0 ) 1 = cx y ,  H y R x ≤ ≤ ≤ ≤ 0 , 0  (7) 
2(,, 0 ) 1 = cx y ,  H y R x ≤ ≤ ≤ ≤ 0 , 0  (8) 
3(,, 0 ) 1 = cx y ,  H y R x ≤ ≤ ≤ ≤ 0 , 0  (9) 
 
1(,,) 0 = cx yt ,    f t t ≤ < 0 ,  H y R x ≤ ≤ = 0 , o r   H y R x = ≤ ≤ , 0  (10) 
2(,,) 0 = cx y t ,   f t t ≤ < 0 ,  H y R x ≤ ≤ = 0 ,  or  H y R x = ≤ ≤ , 0  (11) 
3(,,) 0 = cx y t ,    f t t ≤ < 0 ,  H y R x ≤ ≤ = 0 ,  or  H y R x = ≤ ≤ , 0  (12) 
 
The fractional drug release of the three ingredients is expressed as follows: 
Ω
1
() 1 , 1 ,2 ,3 =− = ∫ ii Rt c d v i
S
, (13) 
where S is the area of the axial cross-sectional domain Ω. 
 
Finite element approach to solving the model problem 
The numerical solution of the nonlinear initial boundary value problem (1-10) is sought in a 
FE form: 
1
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where   are the shape interpolation functions corresponding to the current FE 
discretization of the domain  , and 
, 1, ..., = p Np M
Ω 123 , , , 1, ..., ppp ccc p M =  are the nodal values of the 
water and drug concentrations, respectively;   are vectors with elements 
. The upper notation (⋅)
N C C C , , , 3 2 1
p p p p N c c c , , , 3 2 1
T means a vector transposition. 
 
Applying the semi-discrete Galerkin method to equations (1)-(3), as it is done in [1, 2], the 
equivalent initial matrix problem for the vector functions   is obtained:  3 2 1 , , C C C
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where  ,  are FE matrices generated under the chosen FE mesh as 
follows: 
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The unit vector is denoted with I. 
 
The following non-linear matrix equations are obtained after integration of (13)-(15) by using 
a two-point time difference scheme: 
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The lower index of the FE matrices and the upper one of the vectors corresponds to the 
considered time level under the introduced time difference mesh.  
 
In order to avoid equations nonlinearity, the following predictor-corrector scheme is 
proposed:  
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where  ,  ,   are evaluated at the obtained from (21) predictor solutions 
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The scheme correctness is investigated and the following sufficient condition for its initial 
stability is derived: 
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where  1
~
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Numerical results 
In order to validate the proposed approach (including the explicit relations between the 
current porosity and FE concentrations as well as the numerical scheme and noncommercial 
program) two numerical examples for the release of  IFN-α/ HP-β-CD (1:3) and PEG from 
cylindrical tristearin-based implants with sizes of R = 0.25 cm and 2H = 0.23 cm and weight 
50mg are performed. The real time step used when calculating is approximately 14 minutes, 
which satisfies the initial stability condition (23). 
 
Example 1. The drug (INF-α) diffusion parameter is evaluated for three different levels of 
initial PEG content, fitting the model with available experimental data [4, 8] under  0 0.02 = ε  
[5],   
72 1
2 1.1 10 cm s ,
−− =× ⋅ cr D
72
3 1.7 10 cm s
1 − − = ×⋅ cr D , 
3
1 0.028 g cm ,
− =⋅ in c  
, 
3
2 0.084g cm
− =⋅ in c
33
3 0.056 g cm , 0.112 g cm , 0.224 g cm in c
3 − − = ⋅⋅
− ⋅
10 cm s
  for 5%, 10%, 20% 
PEG, respectively [8], assuming  the value of the average protein density 1.4 g⋅cm
-3 [3]. The 
obtained values of   are 1.4 cr D1
821 − − ×⋅
821 4.5 10 cm s
− − × ⋅
1
1
,   and   for 
5%, 10% and 20% PEG, respectively. Fig. 1 and Fig. 2 show the fit of the proposed model to 
the experimental value for the considered levels of PEG. 
82 4.8 10 cm s
−− ×⋅
 
The numerical results for INF-α release ( ), corresponding to the obtained in [8] value of 
the drug diffusion parameter
) ( 1 t R
82
1 5.9 10 cm s
− − =× ⋅ cr D  for 10% PEG are presented in Fig. 1 
(profile 2). It is obvious that the experimental data are in better correspondence with the 
profile 1 in Fig. 1 (corresponding to our estimation) than with the profile 2.  
 
In order to illustrate the advantages of the proposed approach in respect to the classical 
diffusion theory the drug diffusivity is also estimated for the three levels of PEG: 
. The 
obtained profiles (dashed lines) show not enough good agreement with the experimental data. 
921 821 82
11 1 2 . 51 0c m s, 0 . 7 51 0c m s, 1 . 51 0c m s
−− −− − =× ⋅ = × ⋅ =× ⋅ class class class DD D
1 −
 
Fig. 3 represents the comparison of the numerical results for PEG as an important release 
modifier ( ) with the available experimental data [8], using the obtained value of the 
drug diffusion parameter. 
) ( 3 t R
 
It is established an initial burst release (up to the first or second day) for each of the two 
compounds followed by a sustained liberation (within a period of at least 20 days).   
The numerical results obtained by using the proposed approach are in very good 
correspondence with the experimental data. The superior fitting of the model release profiles 
is observed after the 7
th day for IFN-α and after the 4
th day for PEG. 
 
Example 2. Numerical simulation of IFN-α release and implant porosity change is performed 
for different values of the initial implant porosity   at 10% PEG using the obtained value 
for .  
0 ε
cr D1
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Fig. 1 Numerical results of IFN-α release compared with experimental data at 10% IFN-α/HP-
β-CD and two levels of initial PEG loading: profile 1 – new model results for 10% PEG at 
; profile 2 – new model results for 10% PEG at 
82
1 4.5 10 cm s
− =× ⋅ cr D
1 −
1 − = cr D1
82 5.9 10 cm s
− × ⋅ ; profile 3 – new model results for 5% PEG at 
; dashed profiles – classical diffusion results for 5% and 10% PEG 
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Fig. 2 Numerical results of IFN-α release compared with experimental data  
at 10% IFN-α/HP-β-CD and 20% initial PEG loading;  
continuous profile – new model results; dashed profile – classical diffusion results 
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Fig. 3 Numerical results for   compared with the available experimental data  
for PEG release at 10% initial loading at the presence of 10% IFN-α/HP-β-CD 
) ( 3 t R
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The numerical curves in Fig. 4b demonstrate that the porosity change reaches its steady state 
within the first week for each considered value of  . This result explains the obtained 
significant effect of the initial porosity during the first week (e.g. 55% against 70% drug 
release at 4
0 ε
th day) (Fig. 4a).  
 
048 1 2 1 6 2 0      0 4 8 12 16 20
0
0.05
0.1
0.15
0.2
0.25
Time [days]
Porosity
change
1
2
3
1-  o= 0.5%; 2 -  o= 5%; 3 -  o= 10%
 
0
0.2
0.4
0.6
0.8
1
INF-
release
Time [d]
1
2
3
1-  o= 0.5%; 2-  o= 5%; 3-  o= 10%
(a)       (b) 
Fig. 4 Effect of the initial implant porosity:  
(a) INF-α release; (b) implant porosity increase 
 
Conclusion 
A new approach to modeling drug release kinetics from lipid implants is proposed describing 
simultaneous diffusion of INF-α (drug), HP-β-CD (stabilizer) and PEG (drug release 
modifier). Explicit mathematical expressions for the concentrations dependent diffusivities of 
the three compounds within each element of the domain are derived, taking into account the 
initial and current porosity.  
 
A hybrid numerical scheme based on FE domain discretization and time difference method, as 
well as computational technique, was developed. Its validation was realized on the basis of 
available experimental data for INF-α / HP-β-CD and PEG under different levels of initial 
PEG loading. A detailed estimation of INF-α critical diffusion parameter in comparison with 
the drug diffusivity value is performed by fitting the new approach and the classical diffusion 
theory  to the experimental data for 3 different PEG contents (5, 10 and 20%) using one and 
the same values of HP-β-CD and PEG diffusion parameters (much bigger than  ) [8].  
It is established a very good correspondence between the new model profiles and the 
experimental data. As the values of   for 10 and 20% PEG are very close (about 5% 
difference) the drug release profile for 20% PEG (as well as for 15% PEG) could be simulated 
with an admissible accuracy using the estimation of INF-α diffusion parameter obtained for 
10% PEG in order to avoid an expensive experiment. 
cr D1
cr D1
 
The presented numerical simulation of the protein release simultaneously with the current 
porosity increase illustrates the initial burst drug liberation for an initial implant porosity of 
the range of 0.5%÷10%.  
 
The presented approach and the computational technique thereby proposed can be used as a 
fast and reliable simulation tool when designing a range of lipid implants for sustained drug 
delivery. 
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